Skip to main content

Table 1 The P values are resultant from Pearson χ 2 test of association or Fishers Exact when an asterisk is included

From: Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer

Variable Calpain-9 expression in total patient cohort Calpain-9 expression in patients that received endocrine therapy
Low High P value Low High P value
Age       
  ≤40 years 36 (4.6%) 40 (5.1%) 0.025 4 (1.4%) 2 (0.7%) 0.695*
  >40 years 429 (54.8%) 278 (35.5%) 160 (54.1%) 130 (43.9%)
Size       
  ≤2 cm 296 (38.0%) 166 (21.3%) 0.001 88 (29.7%) 56 (18.9%) 0.055
  >2 cm 166 (21.3%) 151 (19.4%) 76 (25.7%) 76 (25.7%)
Stage       
  1 294 (37.7%) 168 (21.6%) 0.009 70 (23.6%) 53 (17.9%)  
  2 128 (16.4%) 115 (14.8%) 73 (24.7%) 64 (21.6%) 0.784
  3 39 (5.0%) 35 (4.5%) 21 (7.1%) 15 (5.1%)  
Grade       
  1 87 (11.2%) 48 (6.2%) 0.255 8 (2.7%) 8 (2.7%) 0.498
  2 155 (19.9%) 101 (13.0%) 53 (17.9%) 50 (16.9%)
  3 220 (28.2%) 168 (21.6%) 103 (34.8%) 74 (25.0%)
Nottingham prognostic index       
  <3.4 158 (20.3%) 71 (9.1%) 0.002 7 (2.4%) 7 (2.4%) 0.909
  3.4-5.4 219 (28.2) 176 (22.7%) 117 (39.5%) 94 (31.8%)
  >5.4 83 (10.7%) 70 (9.0%) 40 (13.5%) 31 (10.5%)
Basal status       
  Non-basal 351 (46.9%) 240 (46.9%) 0.582 138 (48.6%) 104 (36.6%) 0.257
  Basal 90 (12.0%) 68 (9.1%) 20 (7.0%) 22 (7.7%)
ER status       
  Negative 105 (13.8%) 97 (12.8%) 0.014 26 (9.0%) 29 (10.0%) 0.180
  Positive 345 (45.5%) 212 (27.9%) 134 (46.4%) 100 (34.6%)
PgR status       
  Negative 183 (24.3%) 138 (18.3%) 0.246 64 (22.6%) 51 (18.0%) 0.257
  Positive 265 (35.1%) 168 (22.3%) 96 (33.9%) 72 (25.4%)
HER2 status       
  Negative 394 (51.5%) 264 (34.5%) 0.099 131 (45.5%) 111 (38.5%) 0.765
  Positive 55 (7.2%) 52 (6.8%) 26 (9.0%) 20 (6.9%)
Lymphovascular invasion       
  Negative 255 (36.9%) 168 (26.1%) 0.490 82 (32.2%) 76 (29.8%) 0.164
  Positive 127 (19.7%) 94 (14.6%) 59 (23.1%) 38 (14.9%)
  1. Significant P values are indicated by bold. The immunohistochemistry cohort was comprised of 783 patients; however, scores were not available for every patient for each marker. The number of observations for each marker is shown for each clinicopathological variables and percentage in parentheses. NPI is Nottingham prognostic index, ER is oestrogen receptor, PgR is progesterone receptor.